Senores Pharma. (544319) Aug 2026 Filing Analysis

The original facility plan was scaled down and the IPO proceeds were redirected primarily to oral-solid capacity at the US and India sites. Management said sterile injectables would proceed as a smaller pilot project, with execution pushed to the latter half of FY27. This is a material scope and timing revision, not a cancellation. (1 revised across 1 tracked commitment)

Regulated Markets revenue grew from Rs. 107 Cr in Q2 FY26 to Rs. 127.8 Cr in Q1 FY27, an increase of approximately 19.4%. Its share of total revenue was about 66% in Q2 FY26 (Rs. 107 Cr of Rs. 162 Cr) and 71% in Q1 FY27. Management described the segment as growing on product launches and portfolio expansion. The segment's EBITDA margin was 44% in Q2 FY26 versus approximately 40% in Q1 FY27, so revenue and share expanded while the reported margin was lower. (5 expanding across 1 engine)

Emerging Markets revenue was Rs. 32 Cr in Q2 FY26, around 20% of total revenue, and Rs. 37.6 Cr in Q1 FY27, around 21%. This is an increase of approximately 17.5% between the quarters. In the older period, H1 FY26 revenue was Rs. 61 Cr, only 4% above H1 FY25; management cited delayed commercial orders, currency weakness and geopolitical disruption. The later baseline reports 29.6% year-over-year growth and an approximately 14% margin, indicating stronger recent growth and profitability than the earlier 6.2% H1 FY26 margin. (5 expanding across 2 engines)

Emerging Markets revenue increased from Rs. 26.1 Cr in Q3 FY25 to Rs. 38.4 Cr in Q3 FY26, up 47.5%. Its 9M revenue share was about 20.9%, essentially unchanged from about 29.4%? The 9M share rose from 29.4%? No: revenue of Rs. 84.6 Cr against Rs. 287.4 Cr total income equals 29.4%; current Rs. 99.1 Cr against Rs. 474.3 Cr equals 20.9%, so the share contracted despite revenue growth. The company reported 9M EBITDA margin of 9%, versus 13% in Q3 FY26 and about 1% in Q3 FY25. (4 expanding, 1 shifted across 1 engine)

Senores expanded approved ANDAs from 12 in Q3 FY25 to 46 in Q3 FY26, while commercialized ANDAs rose from 11 to 18. The approved pipeline is growing rapidly, but the presentation does not supply enough intermediate quarterly data to show whether the pace itself is increasing or slowing. (5 accelerating across 5 signals, 1 leading indicator)

FY26 regulated-market revenue was Rs. 427.4 crore, up 74.6% year on year and representing 64% of total income. The Q4 year-on-year growth rate was 83.0%, higher than the FY26 full-year growth rate, indicating stronger growth in the latest quarter shown. The presentation does not provide a Q1 FY27 result, so its claimed Q1 figure is not included. (4 accelerating, 1 decelerating across 5 signals)

The company is targeting specialty products already marketed in the US for earlier launches in emerging markets. Named products include sugammadex, ferric carboxymaltose, tofacitinib, sacubitril plus valsartan, apixaban and eltrombopag olamine. The presentation gives no market-specific launch dates or expected revenue contribution.

Emerging-market revenue grew 47.5% year over year in Q3 FY26, while nine-month revenue grew 17%. The quarterly growth rate was materially stronger than the nine-month rate, and management said 56 newly approved products were expected to be commercialized in the coming quarter. The transcript reports 450 registered products and more than 850 under registration; the newer extracted figures and FY27 revenue estimate are not in this document. (3 accelerating, 2 new trend across 5 signals, 2 leading indicators)

In Dec 2025, Senores described a strong US presence and said Apnar would add access to the UK and Canada, where its presence was limited. This indicates a diversification plan, but the presentation gives no sales mix or evidence that the new markets had yet reduced concentration. The Aug 2026 baseline reports 71% of Q1 FY27 revenue from regulated markets, so exposure remains high; no comparable earlier revenue share is provided to measure the change. (1 insufficient_data, 1 intensifying, 1 high-severity)

The Dec 2025 presentation identifies five acquired ANDAs, of which three were validated and qualified, with commercialization expected to begin immediately. By Aug 2026, the baseline reports 35 approved ANDAs still unlaunched, indicating a much larger execution burden than the five-product acquisition described earlier. The risk has intensified in scale, although the documents do not establish whether the five acquired ANDAs themselves launched or how they performed. (5 intensifying, 1 high-severity)

The presentation says ₹7 crore of the ₹107 crore IPO allocation for the Atlanta sterile-injectables facility had been used by December 31, 2025, leaving ₹100 crore unutilized. It also expected the third and fourth oral-solid lines by Q4 FY26. The later baseline describes a shift toward oral-solid capacity and a smaller, later injectable pilot, indicating that the injectable opportunity was scaled back or postponed. Severity rises from LOW to MEDIUM. (2 intensifying)

In Nov 2025, regulated markets were the largest business: H1 revenue was ₹197 crore of ₹300 crore, or about 66%. Management expected the share to remain around 65% as both regulated and other businesses grew. The Aug 2026 baseline reports 71% of Q1 FY27 revenue from regulated markets, indicating greater concentration over time. Trajectory is INTENSIFYING; severity rises from MEDIUM in this earlier period to HIGH in the baseline. (5 intensifying)

USFDA compliance is a serious potential earnings risk because the company relies on US-regulated manufacturing and product approvals. The presentation reports no warning letter or inspection problem; it instead says the Atlanta facility received no Form 483 observations. This is a risk to monitor, not a current disclosed violation. [REGULATORY]